https://www.selleckchem.com/pr....oducts/filanesib.htm
NAFLD and NASH exist between these physician groups, with knowledge being particularly low among primary care doctors and endocrinologists. The use of a simple non-invasive screening algorithm may help to identify the right patients for clinical trials, which in turn will be vital to the development of effective and well-tolerated treatments for this increasingly ubiquitous condition. Substantial gaps in knowledge of the differences between NAFLD and NASH exist between these physician groups, with knowledge being particularly low amon